Acorda Therapeutics Stock Book Value Per Share

Acorda Therapeutics fundamentals help investors to digest information that contributes to Acorda Therapeutics' financial success or failures. It also enables traders to predict the movement of Acorda Stock. The fundamental analysis module provides a way to measure Acorda Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acorda Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Acorda Therapeutics Company Book Value Per Share Analysis

Acorda Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

 = 

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Acorda Therapeutics Book Value Per Share

    
  (127.17) X  
Most of Acorda Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acorda Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition

In accordance with the recently published financial statements, the book value per share of Acorda Therapeutics is about -127.169 times. This is much higher than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The book value per share for all United States stocks is 106.58% higher than that of the company.

Acorda Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acorda Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acorda Therapeutics could also be used in its relative valuation, which is a method of valuing Acorda Therapeutics by comparing valuation metrics of similar companies.
Acorda Therapeutics is currently under evaluation in book value per share category among its peers.

Acorda Fundamentals

Pair Trading with Acorda Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in Acorda Stock

If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope